

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ocumension Therapeutics
歐康維視生物

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1477)

**POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD
ON AUGUST 31, 2021**

The Board announces that all the resolutions as set out in the Notice were duly passed by the Shareholders as ordinary resolutions by way of poll at the Extraordinary General Meeting.

The board of directors (the “**Board**”) of Ocumension Therapeutics (the “**Company**”) is pleased to announce the poll results of the extraordinary general meeting of the Company (the “**Extraordinary General Meeting**”) held at Taishan Meeting Room, 5th Floor, Want Want Plaza, No. 211 Shimen Yi Road, Jing’an District, Shanghai, the People’s Republic of China at 10:00 a.m. on Tuesday, August 31, 2021.

Reference is made to the Company’s circular (the “**Circular**”) in connection with the Extraordinary General Meeting and notice of the Extraordinary General Meeting (the “**Notice**”) dated August 11, 2021. Unless the context requires otherwise, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

The voting results in respect of the resolutions proposed at the Extraordinary General Meeting were as follows:

Ordinary Resolutions		Number of Votes (%)	
		For	Against
1.	Subject to and conditional upon the Listing Committee of the Stock Exchange granting the approval for the listing of, and the permission to deal in, Shares to be issued pursuant to the exercise of the share options which may be granted under the 2021 Share Option Scheme, to approve and adopt the 2021 Share Option Scheme, and authorize the Directors to do all such acts and to enter into all such transactions, arrangements and agreements as may be necessary or expedient in order to give full effect to the 2021 Share Option Scheme;	442,706,006 (88.859430%)	55,503,366 (11.140570%)

Ordinary Resolutions			Number of Votes (%)	
			For	Against
2.	(a)	To approve and confirm the conditional grant of Options to Mr. Liu in accordance with the terms of the 2021 Share Option Scheme (the “ Options Grant ”), subject to all applicable laws, rules, regulations and the applicable grant letter;	442,706,006 (88.859430%)	55,503,366 (11.140570%)
	(b)	To authorize any one or more of the directors of the Company, with the exception of Mr. Liu, to exercise the powers of the Company to allot and issue the ordinary shares of the Company pursuant to the Option Grant (the “ Option Shares ”) in accordance with the terms of the 2021 Share Option Scheme, such that the Option Shares shall rank <i>pari passu</i> in all respects among themselves and with the existing ordinary shares in issue at the date of the allotment and issuance of the Option Shares, and that he/she/they, be and is/are hereby authorized to take such actions, do such things, which in their opinion may be necessary, desirable or expedient for the purpose of giving effect to and/or to implement the transactions contemplated in 2(a) above;	442,456,406 (88.809330%)	55,752,966 (11.190670%)
3.	(a)	To approve and confirm the conditional grant of Awards to Mr. Liu and Dr. Hu in accordance with the terms of the 2021 Share Award Scheme, subject to all applicable laws, rules, regulations and the applicable grant letter (the “ Awards Grant ”);	442,928,506 (88.904090%)	55,280,866 (11.095910%)
	(b)	To authorize any one or more of the directors of the Company, with the exception of Mr. Liu and Dr. Hu, to exercise the powers of the Company to allot and issue the ordinary shares of the Company pursuant to the Awards Grant (the “ Award Shares ”) under the Connected Grant Specific Mandate granted to the Directors by the shareholders of the Company at the Extraordinary General Meeting in accordance with the terms of the 2021 Share Award Scheme, such that the Award Shares shall rank <i>pari passu</i> in all respects among themselves and with the existing ordinary shares in issue at the date of the allotment and issuance of the Award Shares, and that he/she/they, be and is/are hereby authorized to take such actions, do such things, which in their opinion may be necessary, desirable or expedient for the purpose of giving effect to and/or to implement the transactions contemplated in 3(a) above;	442,928,506 (88.904090%)	55,280,866 (11.095910%)

Ordinary Resolutions			Number of Votes (%)	
			For	Against
4.	(a)	Subject to and conditional upon the Listing Committee of Stock Exchange granting the approval for the listing of, and the permission to deal in, Shares to be issued pursuant to the 2021 Share Award Scheme, to granted the Directors a specific mandate to allot and issue up to 3% of Shares as of the Latest Practicable Date pursuant to the 2021 Share Award Scheme and the Articles of Association and for the purpose of distribution of Shares pursuant to the 2021 Share Award Scheme (the “ Award Scheme Specific Mandate ”), provided that this Award Scheme Specific Mandate shall be in addition to, and shall not prejudice or revoke any existing or such other general or special mandates which may from time to time be granted to the Directors prior to the passing of this resolution;	442,738,506 (88.865953%)	55,470,866 (11.134047%)
	(b)	Subject to and conditional upon the Listing Committee of Stock Exchange granting the approval for the listing of, and the permission to deal in, Shares to be issued pursuant to the 2021 Share Award Scheme, and the passing of resolution 4(a) above, to grant the Directors a specific mandate to allot and issue up to 13,152,000 Shares under the Awards Grant pursuant to the 2021 Share Award Scheme and the Articles of Association (the “ Connected Grant Specific Mandate ”), provided that the Connected Grant Specific Mandate shall be in addition to, and shall not prejudice or revoke any existing or such other general or special mandates (other than the Award Scheme Specific Mandate) which may from time to time be granted to the Directors prior to the passing of this resolution.	442,928,506 (88.904090%)	55,280,866 (11.095910%)

Please refer to the Notice for the full text of the resolutions proposed at the Extraordinary General Meeting.

As more than 50% of the votes were cast in favour of each of the above resolutions, all the resolutions were passed as ordinary resolutions at the Extraordinary General Meeting.

The total number of issued Shares as of the date of the Extraordinary General Meeting was 631,205,380 Shares, which was the total number of Shares entitling the Shareholders to attend and vote for or against all resolutions. Mr. Liu, being the Grantee under the 2021 Share Option Scheme and the Connected Grantee under the 2021 Share Award Scheme, holding a total of 5,836,730 Shares, which represents approximately 0.924696% of the issued share capital of the Company as of the date of the Extraordinary General Meeting, was required to and did abstain from voting on all of the above ordinary resolutions. Dr. Hu, being the Connected Grantee under the 2021 Share Award Scheme, holding a total of 929,243 Shares, which represents approximately 0.147217% of the issued share capital of the Company as of the date of the Extraordinary General Meeting, was required to and did abstain from voting on the ordinary resolutions 3 and 4 above.

Save as aforesaid, there were (a) no Shares entitling the holders to attend and abstain from voting in favour at the Extraordinary General Meeting as set out in rule 13.40 of the Listing Rules, (b) no restrictions on any Shareholders casting votes on any of the proposed resolutions at the Extraordinary General Meeting, and (c) no Shareholders being required under the Listing Rules to abstain from voting on the resolutions proposed at the Extraordinary General Meeting and no Shareholders stating his/her/its intention in the Circular to vote against or to abstain from voting on the resolutions proposed at the Extraordinary General Meeting.

Computershare Hong Kong Investor Services Limited, the Hong Kong branch share registrar and transfer office of the Company, acted as the scrutineer for counting of votes at the Extraordinary General Meeting.

By order of the Board
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Non-executive Director

Hong Kong, August 31, 2021

As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive Directors, Dr. Lian Yong CHEN, Dr. Wei LI, Mr. Yanling CAO and Ms. Yumeng WANG as non-executive Directors, and Mr. Ting Yuk Anthony WU, Mr. Lianming HE and Mr. Yiran HUANG as independent non-executive Directors.